No abstract available
Publication types
-
Letter
-
Research Support, N.I.H., Extramural
MeSH terms
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal, Humanized / administration & dosage
-
Antibodies, Monoclonal, Humanized / adverse effects
-
Betacoronavirus / immunology
-
Biological Products / administration & dosage
-
Biological Products / adverse effects*
-
COVID-19
-
Clinical Decision-Making
-
Clinical Trials, Phase II as Topic
-
Clinical Trials, Phase III as Topic
-
Coronavirus Infections / epidemiology
-
Coronavirus Infections / immunology*
-
Coronavirus Infections / prevention & control
-
Coronavirus Infections / transmission
-
Humans
-
Interleukin-23 Subunit p19 / antagonists & inhibitors*
-
Interleukin-23 Subunit p19 / metabolism
-
Odds Ratio
-
Pandemics / prevention & control
-
Pneumonia, Viral / epidemiology
-
Pneumonia, Viral / immunology*
-
Pneumonia, Viral / prevention & control
-
Pneumonia, Viral / transmission
-
Psoriasis / drug therapy*
-
Psoriasis / immunology
-
Respiratory Tract Infections / chemically induced
-
Respiratory Tract Infections / epidemiology*
-
Respiratory Tract Infections / immunology
-
Respiratory Tract Infections / prevention & control
-
Risk Assessment
-
SARS-CoV-2
-
Signal Transduction / drug effects
-
Signal Transduction / immunology
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Biological Products
-
IL23A protein, human
-
Interleukin-23 Subunit p19
-
guselkumab
-
risankizumab
-
tildrakizumab